Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10
ProQR Therapeutics N.V.January 7, 2021 GMT
Top-line results expected H1 2022
Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced it has completed patient enrollment in its Phase 2/3